Clinical Trials Logo

KRAS G12C Mutant Solid Tumors clinical trials

View clinical trials related to KRAS G12C Mutant Solid Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT06435455 Not yet recruiting - Clinical trials for KRAS G12C Mutant Solid Tumors

GH21 Combined With D-1553 With Advanced Solid Tumors

Start date: July 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This s a multi-center, open-label phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of GH21 combined with D-1553 in patients with advanced or metastatic solid tumors harboring KRAS G12C mutation.

NCT ID: NCT05358249 Recruiting - Colorectal Cancer Clinical Trials

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

KontRASt-03
Start date: October 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.

NCT ID: NCT04699188 Recruiting - Lung Cancer Clinical Trials

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

KontRASt-01
Start date: February 24, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a particular treatment arm, dose expansion will assess the anti-tumor activity and further assess the safety, tolerability, and PK/PD of each regimen at the maximum tolerated dose / recommended dose or lower dose.